Longhorn Vaccines Presents New Antibody Data

Preclinical results show promise for broad-spectrum anti-bacterial treatment

Mar. 31, 2026 at 2:36pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph revealing the intricate molecular structure of a bacterial cell, conceptually illustrating the development of a new antibacterial therapy.Cutting-edge X-ray imaging technology offers a glimpse into the intricate inner workings of a potential new antibacterial treatment.Washington Today

Longhorn Vaccines and Diagnostics, a biopharmaceutical company, has announced new preclinical data on its broad-spectrum anti-bacterial monoclonal antibody LHNVD-501. The data suggests the antibody could be a potential treatment for a wide range of bacterial infections.

Why it matters

The development of new antibacterial treatments is crucial as antibiotic resistance continues to grow globally. LHNVD-501 could represent an innovative approach to addressing this public health challenge by targeting bacteria through a different mechanism than traditional antibiotics.

The details

Longhorn's preclinical studies demonstrated that LHNVD-501 was effective against a diverse panel of Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. The antibody was shown to neutralize bacterial toxins and enhance the activity of the host immune system to clear infections.

  • The preclinical data was presented on March 31, 2026.

The players

Longhorn Vaccines and Diagnostics

A biopharmaceutical company developing new treatments for infectious diseases.

LHNVD-501

Longhorn's broad-spectrum anti-bacterial monoclonal antibody.

Got photos? Submit your photos here. ›

What’s next

Longhorn plans to advance LHNVD-501 into clinical trials to further evaluate its safety and efficacy in treating bacterial infections.

The takeaway

Longhorn's novel antibody-based approach represents a promising new tool in the fight against antibiotic-resistant bacteria, which pose a growing threat to global health.